Resmed Inc Stock Today
| RMD Stock | USD 232.98 6.50 2.71% |
PerformanceVery Weak
| Odds Of DistressLow
|
ResMed is trading at 232.98 as of the 16th of February 2025, a 2.71 percent decrease since the beginning of the trading day. The stock's lowest day price was 232.76. ResMed has only a 7 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Note, on June 14, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of ResMed Inc's common stock.
Business Domain Health Care Equipment & Services | IPO Date 2nd of June 1995 | Category Healthcare | Classification Health Care |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. The company has 146.87 M outstanding shares of which 8.3 M shares are at this time shorted by investors with about 8.77 days to cover. More on ResMed Inc
Moving together with ResMed Stock
| 0.7 | COO | Cooper Companies, Downward Rally | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
ResMed Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Michael Farrell | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Obamacare Repeal (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [RENO DE MEDICI, Reno De Medici S.p.A] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NYSE Composite, SP 500 Index, SPASX 50, SPASX 100, Australia All Ordinaries, SPASX 200 Accumulated, SPASX 300, SPASX 200, Obamacare Repeal, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsResMed can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ResMed's financial leverage. It provides some insight into what part of ResMed's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ResMed Inc (RMD) is traded on New York Stock Exchange in USA. It is located in 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 and employs 34 people. ResMed is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 34.22 B. ResMed Inc runs under Health Care Equipment & Supplies sector within Health Care industry. The entity has 146.87 M outstanding shares of which 8.3 M shares are at this time shorted by investors with about 8.77 days to cover.
ResMed Inc has about 273.71 M in cash with 1.4 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87.
Check ResMed Probability Of Bankruptcy
Ownership AllocationResMed owns a total of 146.87 Million outstanding shares. Over half of ResMed's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that on June 14, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of ResMed Inc's common stock.
Check ResMed Ownership Details
ResMed Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-09-30 | 756 K | |
| Ubs Asset Mgmt Americas Inc | 2024-09-30 | 742.4 K | |
| Greenvale Capital Llp | 2024-09-30 | 700 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 676.4 K | |
| Los Angeles Capital Management Llc | 2024-12-31 | 668.9 K | |
| Amundi | 2024-09-30 | 566.4 K | |
| Congress Asset Management Company, Llp | 2024-12-31 | 524 K | |
| Lgt Capital Partners Ltd. | 2024-09-30 | 520.1 K | |
| Tandem Investment Advisors Inc | 2024-12-31 | 501.7 K | |
| Vanguard Group Inc | 2024-09-30 | 18 M | |
| Blackrock Inc | 2024-09-30 | 11.9 M |
ResMed Historical Income Statement
ResMed Stock Against Markets
ResMed Corporate Directors
| Ronald Taylor | Lead Independent Director | Profile | |
| Harjit Gill | Independent Director | Profile | |
| Carol Burt | Independent Director | Profile | |
| Jan Witte | Independent Director | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.649 | Dividend Share 2.02 | Earnings Share 8.48 | Revenue Per Share | Quarterly Revenue Growth 0.103 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.